NYSE:NNVC NanoViricides (NNVC) Stock Price, News & Analysis → Urgent Nvidia Warning (From Altimetry) (Ad) Free NNVC Stock Alerts $1.20 +0.07 (+6.19%) (As of 05/2/2024 ET) Add Compare Share Share Today's Range$1.12▼$1.2050-Day Range$1.10▼$1.4152-Week Range$1.00▼$2.00Volume11,489 shsAverage Volume32,931 shsMarket Capitalization$14.14 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOptions ChainSEC FilingsSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOptions ChainSEC FilingsSocial Media Get NanoViricides alerts: Email Address Ad InvestorPlaceHave You Seen Elon’s New A.I. Device? (Picture Inside)A strange new era for mankind is upon us... And it's all thanks to Elon Musk's latest creation. Click here to see this strange device you could be wearing some day. Elon believes A.I. is advancing so fast...This strange new device to protect us against that A.I. threat... About NanoViricides Stock (NYSE:NNVC)NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company's product portfolio includes NV-CoV-2, nanoviricide drug which is in phase 1a/1b clinical trails for the treatment of Covid; and NV-CoV-2 Oral Syrup, and NV-CoV-2 Oral Gummies, a semi-solid fixed-dose form which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric cases. It also offers NV-CoV-2 Solution for injection, infusion, and inhalation to treat severe cases that are not yet hospitalized would be best performed by an injection; and injectable solution can be delivered directly into the lungs as a fog created using standard portable battery operated nebulizer devices which enables action at the most important site of infection by a respiratory virus, such as coronaviruses, RSV, influenzas, human meta-pneumovirus, certain adenoviruses, and other infections, that can lead to severe pneumonia. In addition, the company provides Nanoviricide, a biomimetic platform technology designed to attack enveloped virus particles to deliver anti-viral payload into infected cells sparing uninfected cells to block replication cycle without toxicity. NanoViricides, Inc. was incorporated in 2005 and is headquartered in Shelton, Connecticut.Read More NNVC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NNVC Stock News HeadlinesMay 1, 2024 | americanbankingnews.comStockNews.com Begins Coverage on NanoViricides (NYSE:NNVC)April 30, 2024 | proactiveinvestors.comNanoViricides completes Phase 1 trial of lead asset NV-387May 2, 2024 | Porter & Company (Ad)The biggest energy story ever? Discover why I’m calling this one of the biggest developments in the global energy market since the shale revolution… why everything you’ve ever been told about Trump’s environmental record is a lie…April 23, 2024 | americanbankingnews.comStockNews.com Initiates Coverage on NanoViricides (NYSE:NNVC)February 26, 2024 | benzinga.comNanoviricides Stock (AMEX:NNVC) Earnings Dates and Earning CallsFebruary 15, 2024 | proactiveinvestors.comNanoViricides boosts liquidity measures and manufacturing capacity to support clinical trialsFebruary 15, 2024 | finance.yahoo.comNanoViricides Has Filed its Quarterly Report - NV-387 Clinical Trial Healthy Subjects Part Successfully Completed, COVID Patient Treatment on the HorizonFebruary 1, 2024 | benzinga.comA New COVID-19 Variant Is Rapidly Spreading Around The Globe, Other Pandemic Threats Exist – What Are The Choices For Treatment?May 2, 2024 | Porter & Company (Ad)The biggest energy story ever? Discover why I’m calling this one of the biggest developments in the global energy market since the shale revolution… why everything you’ve ever been told about Trump’s environmental record is a lie…February 1, 2024 | finance.yahoo.comClinical Trial Demonstration of Safety and Tolerability of NV-CoV-2 Has Implications Beyond COVID Treatment, Explains NanoViricides - NV-387 Could be As Revolutionary as AntibioticsJanuary 29, 2024 | proactiveinvestors.comNanoViricides successfully concludes first-in-human studyJanuary 29, 2024 | proactiveinvestors.comNanoViricides makes progress as it completes dosing in Phase 1a COVID studyJanuary 29, 2024 | finance.yahoo.comSafety in Multiple-Ascending-Dose Healthy Subjects Clinical Trial Part Successfully Established for the NanoViricides Ultra-Broad-Spectrum Antiviral Drug NV-CoV-2 with No Adverse Events FoundJanuary 8, 2024 | benzinga.comNanoViricides, Inc. (NNVC) To Unveil Cutting-Edge Antiviral Breakthroughs At Biotech Showcase™ 2024January 7, 2024 | morningstar.comNanoviricides Inc NNVCJanuary 4, 2024 | finanznachrichten.deNanoViricides, Inc.: NanoViricides to Present at the Biotech Showcase in San FransiscoDecember 1, 2023 | benzinga.comNanoViricides updates progress on Phase 1a/1b clinical trial of antiviral drug candidate NV-387November 28, 2023 | proactiveinvestors.comNanoViricides completes Phase 1a/1b human clinical trial for its broad-spectrum antiviral drugNovember 28, 2023 | finance.yahoo.comThe Phase 1a/1b Human Clinical Trial of NV-CoV-2, the Company’s Broad-Spectrum Antiviral Drug, Has Successfully Completed the First Part (Phase 1a), Reports NanoViricidesNovember 15, 2023 | proactiveinvestors.comNanoViricides continues to progress antiviral drug candidate...November 15, 2023 | finance.yahoo.comNanoViricides Has Filed its Quarterly Report - NV-387 Broad-Spectrum Antiviral in Clinical Trials Has Additional ApplicationsOctober 17, 2023 | proactiveinvestors.comNanoViricides updates investors on Phase 1a/1b trial of antiviral drug candidate for coronavirusOctober 16, 2023 | finance.yahoo.comNanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 (NV-CoV-2) in Phase 1a/1b Clinical Trial is Highly Active Against Coronaviruses as well as RSVOctober 12, 2023 | finance.yahoo.comNanoViricides, Inc. to Present at the Partnership Opportunities in Drug Delivery Conference in Boston on October 16, 2023 at 6:07pm ETSeptember 5, 2023 | finance.yahoo.comNNVC: NanoViricides Begins Clinical Trial of NV-CoV-2August 31, 2023 | finance.yahoo.comNanoViricides progressing well with new Covid studyAugust 29, 2023 | msn.com$NNVC Reports Their Broad-Spectrum Antiviral Drugs Human Clinical Trial Is Progressing SuccessfullySee More Headlines Receive NNVC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NanoViricides and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/14/2024Today5/02/2024Fiscal Year End6/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNYSE:NNVC CUSIPN/A CIK1379006 Webwww.nanoviricides.com Phone(203) 937-6137Fax203-859-5095Employees7Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.81) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-8,590,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-63.97% Return on Assets-58.21% Debt Debt-to-Equity RatioN/A Current Ratio5.59 Quick Ratio5.59 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.28 per share Price / Book0.94Miscellaneous Outstanding Shares11,780,000Free Float11,237,000Market Cap$14.14 million OptionableOptionable Beta0.70 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesDr. Anil R. Diwan Ph.D. (Age 65)Executive Chairman, President, CEO & Secretary Comp: $400kMs. Meeta R. Vyas B.S. (Age 65)M.B.A., SB, MBA, Chief Financial Officer Comp: $129.6kDr. Randall W. Barton Ph.D. (Age 77)Chief Scientific Officer Key CompetitorsTraws PharmaNASDAQ:TRAWRedHill BiopharmaNASDAQ:RDHLMIRA PharmaceuticalsNASDAQ:MIRAImunonNASDAQ:IMNNPurple BiotechNASDAQ:PPBTView All CompetitorsInstitutional OwnershipSimplex Trading LLCBought 1,000 shares on 2/2/2024Ownership: 0.000%View All Institutional Transactions NNVC Stock Analysis - Frequently Asked Questions How have NNVC shares performed in 2024? NanoViricides' stock was trading at $1.02 at the beginning of the year. Since then, NNVC stock has increased by 17.6% and is now trading at $1.20. View the best growth stocks for 2024 here. How were NanoViricides' earnings last quarter? NanoViricides, Inc. (NYSE:NNVC) released its earnings results on Wednesday, February, 14th. The company reported ($0.18) earnings per share for the quarter, topping analysts' consensus estimates of ($0.19) by $0.01. When did NanoViricides' stock split? NanoViricides's stock reverse split on the morning of Tuesday, September 24th 2019. The 1-20 reverse split was announced on Thursday, September 12th 2019. The number of shares owned by shareholders was adjusted after the market closes on Monday, September 23rd 2019. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. How do I buy shares of NanoViricides? Shares of NNVC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSE:NNVC) was last updated on 5/2/2024 by MarketBeat.com Staff From Our PartnersUrgent Nvidia WarningAltimetryA.I. is a Tidal Wave - Here’s What to BuyChaikin AnalyticsTruth about Trump you’ve never heardPorter & CompanyHe Is Giving Away BitcoinCrypto Swap ProfitsThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThe A.I. story nobody is telling you (Read ASAP)TradeSmithAI “wealth window” is closing June 25thParadigm Press4 Cryptos BETTER than BitcoinTrue Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NanoViricides, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.